Prevalence of human papillomavirus among females after vaccine introduction—National Health and Nutrition Examination Survey, United States, 2003–2014
SE Oliver, ER Unger, R Lewis… - The Journal of …, 2017 - academic.oup.com
Background Human papillomavirus (HPV) vaccine was recommended in 2006 for routine
vaccination of US females aged 11–12 years. Most vaccine used through 2014 was …
vaccination of US females aged 11–12 years. Most vaccine used through 2014 was …
Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition …
LE Markowitz, S Hariri, C Lin, EF Dunne… - The Journal of …, 2013 - academic.oup.com
Background. Human papillomavirus (HPV) vaccination was introduced into the routine
immunization schedule in the United States in late 2006 for females aged 11 or 12 years …
immunization schedule in the United States in late 2006 for females aged 11 or 12 years …
Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a …
JA Kahn, LE Widdice, L Ding, B Huang… - Clinical Infectious …, 2016 - academic.oup.com
abstract Background. Human papillomavirus (HPV) vaccine effectiveness and herd
protection are not well established in community settings. Our objective was to determine …
protection are not well established in community settings. Our objective was to determine …
Seroprevalence of 9 human papillomavirus types in the United States, 2005–2006
G Liu, LE Markowitz, S Hariri… - The Journal of …, 2016 - academic.oup.com
Background. A 9-valent human papillomavirus (HPV) vaccine, licensed in 2014, prevents 4
HPV types targeted by the quadrivalent vaccine (6/11/16/18) and 5 additional high-risk (HR) …
HPV types targeted by the quadrivalent vaccine (6/11/16/18) and 5 additional high-risk (HR) …
Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States—National Health and Nutrition Examination Survey, 2003–2006 …
EF Dunne, M Sternberg, LE Markowitz… - Journal of Infectious …, 2011 - academic.oup.com
Abstract The 2003–2006 National Health and Nutrition Examination Surveys were used to
assess human papillomavirus (HPV) types 6, 11, 16, and 18 DNA detection from females …
assess human papillomavirus (HPV) types 6, 11, 16, and 18 DNA detection from females …
Declines in vaccine-type human papillomavirus prevalence in females across racial/ethnic groups: data from a national survey
NM McClung, RM Lewis, JW Gargano, T Querec… - Journal of Adolescent …, 2019 - Elsevier
Purpose To monitor human papillomavirus (HPV) vaccine impact in the US, we evaluated
quadrivalent vaccine (4vHPV)-type prevalence among females aged 14–34 years in the …
quadrivalent vaccine (4vHPV)-type prevalence among females aged 14–34 years in the …
Human papillomavirus vaccine impact and effectiveness through 12 years after vaccine introduction in the United States, 2003 to 2018
HG Rosenblum, RM Lewis, JW Gargano… - Annals of internal …, 2022 - acpjournals.org
Background: Human papillomavirus (HPV) vaccination was introduced in 2006 for females
and in 2011 for males. Objective: To estimate vaccine impact and effectiveness against …
and in 2011 for males. Objective: To estimate vaccine impact and effectiveness against …
Human papillomavirus vaccine coverage in the United States, National Health and nutrition examination survey, 2007–2008
DT La'Shan, S Hariri, M Sternberg, EF Dunne… - Preventive …, 2011 - Elsevier
OBJECTIVES: This study aims to estimate human papillomavirus (HPV) vaccine coverage
by demographic and sexual behavior characteristics 1–2years after vaccine licensure in a …
by demographic and sexual behavior characteristics 1–2years after vaccine licensure in a …
Human papillomavirus vaccination coverage among females and males, National Health and Nutrition Examination Survey, United States, 2007–2016
RM Lewis, LE Markowitz - Vaccine, 2018 - Elsevier
Background Human papillomavirus (HPV) vaccination has been routinely recommended at
age 11–12 years in the United States for females since 2006 and males since 2011 …
age 11–12 years in the United States for females since 2006 and males since 2011 …
Human papillomavirus vaccine effectiveness against HPV infection: evaluation of one, two, and three doses
LE Markowitz, AL Naleway, NP Klein… - The Journal of …, 2020 - academic.oup.com
Background Highly effective human papillomavirus (HPV) vaccines are used in many
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …